Patients with an established histological diagnosis of MCL on lymph-node biopsy, bone marrow biopsy, or extranodal tissue. MedDRA version: 14.1 Level: SOC Classification code 10005329 Term: Blood and lymphatic system disorders System Organ Class: 10005329 - Blood and lymphatic system disorders
Conditions
Interventions
Trade Name: LEVACT*5FL 100MG 2,5MG/ML
Pharmaceutical Form: Powder for solution for infusion
INN or Proposed INN: BENDAMUSTINE
CAS Number: 16506-27-7
Current Sponsor code: NA
Other descriptive name: NA
Sponsors
FONDAZIONE ITALIANA LINFOMI ONLUS
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Previously untreated patients with MCL aged >65 years if they are FIT according to the geriatric CGA assessment. • age 60-65 years not eliglible to high-dose chemotherapy plus transplantation, FIT or UNFIT according to the geriatric CGA assessment. • ECOG performance status =2. • Positivity for cyclin D1 and SOX11 [the latter being mandatory in cases lacking cyclin D1- or t(11;14)-negative], CD20 and CD5. • Adequate renal function (Creatinine clearance >40 mL/min), with preserved diuresis. • Adequate liver function: alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =65 years) yes F.1.3.1 Number of subjects for this age range 57
Exclusion criteria
Exclusion criteria: • Human immunodeficiency virus (HIV) positive. • Previous treatment for lymphoma • Medical conditions or organ injuries that could interfere with administration of therapy. • Active bacterial, viral, or fungal infection requiring systemic therapy. • Seizure disorders requiring anticonvulsant therapy. • Severe chronic obstructive pulmonary disease with hypoxiemia. • History of severe cardiac disease: New York Heart Association (NYHA) functional class III-IV, myocardial infarction within 6 months, ventricular tachyarrhythmias, dilatative cardiomyopathy, or unstable angina. • Uncontrolled diabetes mellitus. • Active secondary malignancy. • Known hypersensitivity or anaphylactic reactions to murine antibodies and proteins, to Bendamustine ormannitol. • Major surgery within 4 weeks of study Day 1. • HBsAg+ • HCVAb+ patients with active viral replication (HCV-RNA+ with AST>2 x normal limit) • Any co-existing medical or psychological condition that would preclude participation in the study or compromise the patient’s ability to give informed consent, or that may affect the interpretation of the results, or render the patient at high risk from treatment complications. • CNS involvement (a diagnostic lumbar puncture will be performed in patients with the blastoid variant of MCL)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective is to determine the activity (complete remission rate according to Cheson 2007 criteria) and safety of age-adjusted Rituximab-Bendamustine-Cytarabine (RBAC500) regimen at the end of treatment in older untreated patients with MCL.;Secondary Objective: The secondary objectives are to determine: - The rate of molecular response (characterized by labs of the FIL) -The progression-free survival (PFS) -The overall survival (OS) -The duration of responses (DOR) -The rate of patients that complete the expected treatment schedule (6 courses) - The rate of patients that are subject to dose reductions or delays;Primary end point(s): Primary efficacy end point of the study is the proportion of CR defined according to Cheson criteria (2007) at the end of treatment (6 or 4 cycles). Primary safety end point is the occurrence of any of the stop treatment criteria or of any episode of relevant toxicity.;Timepoint(s) of evaluation of this end point: 6 o 4 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Secondary end points are MRD defined response, OS, PFS and DOR (Cheson 2007). Molecular response is the proportion of patients with molecular rearrangements at baseline that become negative during treatment, measured by qualitative and quantitative PCR.;Timepoint(s) of evaluation of this end point: OS is measured from enrollment until death from any cause. PFS is measured from the time of enrollment until disease progression, relapse or death from any cause. DOR is measured from the first assessment that documents response (CR or PR) to the date of disease relapse or progression. | — |
Countries
Italy
Contacts
Public ContactSegreteria
Fondazione Italiana Linfomi Onlus
Outcome results
None listed